Media stories about Oncolytics Biotech (NASDAQ:ONCY) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oncolytics Biotech earned a news impact score of 0.01 on Accern’s scale. Accern also gave media coverage about the company an impact score of 48.7015535285678 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several equities analysts recently issued reports on ONCY shares. Zacks Investment Research lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Thursday, June 7th. ValuEngine lowered Oncolytics Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th.
Oncolytics Biotech traded up $0.54, hitting $4.84, on Friday, according to Marketbeat.com. 131,457 shares of the stock traded hands, compared to its average volume of 47,854. Oncolytics Biotech has a 52 week low of $3.58 and a 52 week high of $8.55. The firm has a market capitalization of $71.04 million, a price-to-earnings ratio of -5.69 and a beta of 1.81.
Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Friday, August 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.25). equities research analysts expect that Oncolytics Biotech will post -0.95 earnings per share for the current fiscal year.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Featured Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.